Volition Sponsors Symposium at Veterinary Meeting and Expo
Rhea-AI Summary
VolitionRx (NYSE AMERICAN: VNRX) is sponsoring an industry symposium at the Veterinary Meeting and Expo (VMX) in Orlando, Florida, with a presentation on Monday, January 19, 2026 at 2:45 PM EST by Dr. Sue Ettinger titled "Utilizing the Nu.Q® Vet Cancer Test in Practice."
The company said its Volition Veterinary Diagnostics Development team will staff booth 2243 during the conference, which draws about 20,000 veterinary professionals. Management highlighted using the Nu.Q® Canine Cancer Test during annual or senior-wellness exams to aid earlier cancer detection and support timely care decisions for pet owners.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VNRX gained 0.55%, reflecting a mild positive market reaction. Argus tracked a trough of -2.9% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $187K to the company's valuation, bringing the market cap to $34M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VNRX was down 3.16% while key peers were mixed: ICCM -0.9%, LUNG -8.5%, TELA -0.99%, CTSO -5.23%, and APYX +3.73%. Momentum scanner only flagged WOK at +5.89%, suggesting today’s setup looked stock-specific rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | Financing agreement | Positive | +24.2% | Secured $2.0M gross proceeds via senior secured convertible note and warrant. |
| Jan 08 | Clinical data update | Positive | +24.2% | Reported Nu.Q Vet feline assay data with high specificity and lymphoma detection. |
| Dec 17 | Business review | Positive | +10.3% | Outlined 2025 commercial, clinical, IP milestones and initial Nu.Q Cancer revenues. |
| Dec 11 | Technology update | Positive | +2.6% | Announced Capture-Seq cfDNA enrichment data and projected large liquid biopsy TAM. |
| Dec 08 | Conference abstracts | Positive | -0.7% | Presented lung cancer Nu.Q biomarker data and initial hospital order at conference. |
Recent news on financings and clinical progress for the Nu.Q platform often coincided with positive price reactions, with only one minor divergence on lung cancer abstract data.
Over the last few months, Volition highlighted multiple Nu.Q platform milestones and financing steps. On Dec 08, 2025 and Dec 11, 2025, it reported lung cancer biomarker data and Capture-Seq™ enrichment performance. A broader Business Review 2025 came on Dec 17, 2025. In early Jan 2026, Volition announced breakthrough feline cancer data and a $2.0 million funding package. Today’s VMX symposium sponsorship fits the ongoing commercialization push in veterinary oncology.
Regulatory & Risk Context
The company has an effective Form S-3 shelf registration dated Jul 03, 2025, expiring Jul 03, 2028, with at least 4 associated 424B takedowns. This structure provides flexibility to raise capital through registered offerings when needed, subject to market conditions and usage decisions.
Market Pulse Summary
This announcement highlights Volition’s push to increase Nu.Q Vet Cancer Test adoption by showcasing real‑world use at VMX, a major veterinary meeting with approximately 20,000 professionals. It follows recent clinical data and funding updates that supported the veterinary and human pipelines. Investors may monitor conference feedback, test uptake in routine wellness exams, and future disclosures on revenue growth, financing activity under the existing S-3, and execution against prior clinical milestones.
Key Terms
epigenetics medical
AI-generated analysis. Not financial advice.
Dr. Sue Ettinger, DVM, DACVIM (Oncology) aka "Dr Sue Cancer Vet" will present
"Utilizing the Nu.Q® Vet Cancer Test in Practice" on Monday, January 19 at 2.45pm EST.
Dr. Tom Butera, Chief Executive Officer, Volition Veterinary Diagnostics Development LLC commented:
"We are excited to attend VMX 2026 and are delighted that Dr Sue Ettinger will be sharing her extensive experience with our Nu.Q® Vet Cancer Test.
By incorporating the Nu.Q® Canine Cancer Test into annual checkups or regular senior wellness exams, veterinarians can detect cancer earlier¹ and help pet owners make timely, informed decisions about cancer care.
This is our busiest conference with approximately 20,000 veterinary professionals in attendance and is a great opportunity, along with our partners, to showcase our groundbreaking Nu.Q® Test."
The Volition Veterinary Diagnostics Development team will be available at booth 2243.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of
1. Wilson-Robles, H.M., Bygott, T., Kelly, T.K. et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res 18, 329 (2022). https://doi.org/10.1186/s12917-022-03429-8
View original content:https://www.prnewswire.com/news-releases/volition-sponsors-symposium-at-veterinary-meeting-and-expo-302663403.html
SOURCE VolitionRx Limited
FAQ
What will VolitionRx (VNRX) present at VMX 2026 on January 19?
Where can investors and vets find VolitionRx at VMX 2026 in Orlando?
How many attendees does VMX 2026 expect and why does that matter for VNRX?
What does VolitionRx say about using the Nu.Q® Canine Cancer Test in practice?
Will VolitionRx host demonstrations or personnel at VMX 2026?
Does the VMX symposium sponsorship indicate a regulatory or commercial milestone for VNRX?
